Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it
Maintaining weight loss after medication ends is a difficult transition, prompting researchers to test two practical support options…
Research makes strong case for broader use of GLP1 drugs to protect hearts
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD)…
Semaglutide cuts major heart events, but researchers still cannot fully explain why
A detailed analysis of the SELECT trial examined how much of the reduction in major heart events could…
Discovery of receptor-free signaling reveals better targets for treating autoimmune diseases
Our understanding of how cells interact with each other has been driven for decades by the central concept…
Hedgehog coronaviruses reveal potential pathways for cross-species transmission
Washington State University researchers have discovered how a group of coronaviruses circulating in hedgehogs invades host cells, a…
Could scorpion venom inspire new treatments for liver disease?
From blocking inflammatory immune pathways to disrupting hepatitis viruses, scorpion-derived peptides are attracting attention as potential drug candidates,…
GLP-1 drugs appear psychiatrically safe, but one finding still raises questions
With millions of patients now taking GLP-1 drugs, researchers examined whether concerns about depression and suicidality are supported…
Immune signaling pathway protects newborn heart cells from injury
Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown…
Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…
Newer GLP-1 medications may reduce alcohol-related hospitalization risk
Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…